Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.28
NAS:ANGO's Cash to Debt is ranked lower than
79% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. NAS:ANGO: 0.28 )
Ranked among companies with meaningful Cash to Debt only.
NAS:ANGO' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 6.67 Max: N/A
Current: 0.28
Equity to Asset 0.70
NAS:ANGO's Equity to Asset is ranked higher than
68% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NAS:ANGO: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ANGO' s Equity to Asset Range Over the Past 10 Years
Min: 0.06  Med: 0.85 Max: 0.94
Current: 0.7
0.06
0.94
Interest Coverage 0.30
NAS:ANGO's Interest Coverage is ranked lower than
100% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.78 vs. NAS:ANGO: 0.30 )
Ranked among companies with meaningful Interest Coverage only.
NAS:ANGO' s Interest Coverage Range Over the Past 10 Years
Min: 0.3  Med: 22.03 Max: 74.68
Current: 0.3
0.3
74.68
F-Score: 5
Z-Score: 2.54
M-Score: -2.74
WACC vs ROIC
8.40%
-8.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 0.29
NAS:ANGO's Operating margin (%) is ranked lower than
58% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. NAS:ANGO: 0.29 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ANGO' s Operating margin (%) Range Over the Past 10 Years
Min: -10  Med: 4.67 Max: 13.14
Current: 0.29
-10
13.14
Net-margin (%) -12.32
NAS:ANGO's Net-margin (%) is ranked lower than
65% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. NAS:ANGO: -12.32 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ANGO' s Net-margin (%) Range Over the Past 10 Years
Min: -12.32  Med: 2.32 Max: 8.75
Current: -12.32
-12.32
8.75
ROE (%) -8.08
NAS:ANGO's ROE (%) is ranked lower than
64% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.19 vs. NAS:ANGO: -8.08 )
Ranked among companies with meaningful ROE (%) only.
NAS:ANGO' s ROE (%) Range Over the Past 10 Years
Min: -8.08  Med: 1.31 Max: 7.96
Current: -8.08
-8.08
7.96
ROA (%) -5.76
NAS:ANGO's ROA (%) is ranked lower than
63% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. NAS:ANGO: -5.76 )
Ranked among companies with meaningful ROA (%) only.
NAS:ANGO' s ROA (%) Range Over the Past 10 Years
Min: -5.76  Med: 1.14 Max: 6.98
Current: -5.76
-5.76
6.98
ROC (Joel Greenblatt) (%) 0.11
NAS:ANGO's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.92 vs. NAS:ANGO: 0.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ANGO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -16.13  Med: 12.43 Max: 40.03
Current: 0.11
-16.13
40.03
Revenue Growth (3Y)(%) 4.60
NAS:ANGO's Revenue Growth (3Y)(%) is ranked higher than
50% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NAS:ANGO: 4.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ANGO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.2  Med: 8.75 Max: 25.2
Current: 4.6
3.2
25.2
EBITDA Growth (3Y)(%) 30.20
NAS:ANGO's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. NAS:ANGO: 30.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ANGO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.1  Med: 6.2 Max: 31.9
Current: 30.2
-34.1
31.9
EPS Growth (3Y)(%) -23.40
NAS:ANGO's EPS Growth (3Y)(%) is ranked lower than
82% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. NAS:ANGO: -23.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ANGO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.7  Med: -0.75 Max: 100
Current: -23.4
-39.7
100
» NAS:ANGO's 10-Y Financials

Financials (Next Earnings Date: 2016-10-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ANGO Guru Trades in Q3 2015

Paul Tudor Jones 11,739 sh (New)
Jim Simons 256,851 sh (+18.58%)
Chuck Royce 538,703 sh (+6.53%)
Mario Gabelli 78,000 sh (-2.50%)
» More
Q4 2015

ANGO Guru Trades in Q4 2015

Jim Simons 364,400 sh (+41.87%)
Chuck Royce 640,801 sh (+18.95%)
Mario Gabelli 74,000 sh (-5.13%)
Paul Tudor Jones 10,139 sh (-13.63%)
» More
Q1 2016

ANGO Guru Trades in Q1 2016

Jim Simons 438,500 sh (+20.33%)
Chuck Royce 720,801 sh (+12.48%)
Paul Tudor Jones Sold Out
Mario Gabelli 66,000 sh (-10.81%)
» More
Q2 2016

ANGO Guru Trades in Q2 2016

Joel Greenblatt 14,848 sh (New)
Jim Simons 494,400 sh (+12.75%)
Chuck Royce 752,109 sh (+4.34%)
Mario Gabelli 66,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ANGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:ATRC, NAS:ATRI, NAS:NVCR, NAS:OSUR, NAS:UNIS, OTCPK:NNCSF, NAS:MLAB, NAS:CFMS, NAS:ENTL, NAS:STAA, NAS:LMAT, AMEX:CRHM, NAS:LMNX, NAS:ATRS, OTCPK:GMDTF, NAS:UTMD, NAS:IVTY, NAS:ELGX, NAS:MMSI, AMEX:TRXC » details
Traded in other countries:UG2.Germany,
AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.

AngioDynamics Inc was incorporated in 1988 in Delaware. The Company designs, manufactures & sells medical, surgical & diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease & for use in oncology & surgical settings. Its product offerings fall within three product groupings: Peripheral Vascular, Vascular Access & Oncology/Surgery. The Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. Fluid Management product offering includes the NAMIC Fluid Management portfolio. The NAMIC product line includes an extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers & interventional accessories. These devices are utilized together & allow clinicians to aspirate or inject contrast, saline, remove waste & monitor invasive blood pressures throughout the procedure. Venous products focus on the treatment of varicose veins & consist of its VenaCure EVLT laser system & Sotradecol. VenaCure EVLT laser system products are used in endovascular laser procedures to treat superficial venous disease (varicose veins). Sotradecol (sodium tetradecyl sulfate injection) is an FDA approved sclerosing drug that it distribute through a agreement with the manufacturer. Thrombus Management product offerings includes AngioVac & thrombolytic products. In fiscal 2013, the Company released its AngioVac venous drainage system which includes a Venous Drainage Cannula & Cardiopulmonary Bypass Circuit. The AngioVac devices are for use with other manufacturer's off-the-shelf pump, filter, & reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins & surgical bypass grafts. The Company's other core peripheral vascular products include Angiographic products & accessories, drainage, micro access & other products. Angiographic products & accessories are used during peripheral vascular interventional procedures. Drainage products percutaneously drain abscesses & other fluid pockets. An abscess is a tender inflamed mass that typically must be drained by a physician. Image-guided vascular access, or IGVA, involves the use of imaging equipment to guide the placement of catheters that deliver short-term drug therapies, such as chemotherapeutic agents & antibiotics, into the central venous system. The BioFlo products incorporate Endexo Technology into the manufacturing & design of its Vascular Access products. A peripherally inserted central catheter, or PICC, is a long thin catheter that is inserted into a peripheral vein, typically in the upper arm, & until the catheter tip terminates in a large vein in the chest near the heart to obtain intravenous access. Ports are implantable devices utilized

Ratios

vs
industry
vs
history
Forward P/E 27.03
ANGO's Forward P/E is ranked lower than
69% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.70 vs. ANGO: 27.03 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 31.38
ANGO's Price/Owner Earnings (ttm) is ranked lower than
58% of the 79 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.25 vs. ANGO: 31.38 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ANGO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.22  Med: 29.49 Max: 583.33
Current: 31.38
12.22
583.33
P/B 1.21
ANGO's P/B is ranked higher than
82% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. ANGO: 1.21 )
Ranked among companies with meaningful P/B only.
ANGO' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 0.97 Max: 6.71
Current: 1.21
0.64
6.71
P/S 1.76
ANGO's P/S is ranked higher than
66% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. ANGO: 1.76 )
Ranked among companies with meaningful P/S only.
ANGO' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 1.67 Max: 5.51
Current: 1.76
1.02
5.51
PFCF 17.88
ANGO's PFCF is ranked higher than
72% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.58 vs. ANGO: 17.88 )
Ranked among companies with meaningful PFCF only.
ANGO' s PFCF Range Over the Past 10 Years
Min: 9.96  Med: 27.88 Max: 837.6
Current: 17.88
9.96
837.6
POCF 16.36
ANGO's POCF is ranked higher than
53% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.69 vs. ANGO: 16.36 )
Ranked among companies with meaningful POCF only.
ANGO' s POCF Range Over the Past 10 Years
Min: 8.4  Med: 16.29 Max: 252.67
Current: 16.36
8.4
252.67
EV-to-EBIT 267.93
ANGO's EV-to-EBIT is ranked lower than
98% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.20 vs. ANGO: 267.93 )
Ranked among companies with meaningful EV-to-EBIT only.
ANGO' s EV-to-EBIT Range Over the Past 10 Years
Min: -251.1  Med: 17.1 Max: 548.5
Current: 267.93
-251.1
548.5
EV-to-EBITDA 22.70
ANGO's EV-to-EBITDA is ranked lower than
71% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.23 vs. ANGO: 22.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANGO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -874.8  Med: 16.4 Max: 171.6
Current: 22.7
-874.8
171.6
Shiller P/E 127.36
ANGO's Shiller P/E is ranked lower than
94% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 44.27 vs. ANGO: 127.36 )
Ranked among companies with meaningful Shiller P/E only.
ANGO' s Shiller P/E Range Over the Past 10 Years
Min: 41.92  Med: 79.32 Max: 133.85
Current: 127.36
41.92
133.85
Current Ratio 2.43
ANGO's Current Ratio is ranked lower than
52% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. ANGO: 2.43 )
Ranked among companies with meaningful Current Ratio only.
ANGO' s Current Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5.18 Max: 14.28
Current: 2.43
1.95
14.28
Quick Ratio 1.36
ANGO's Quick Ratio is ranked lower than
64% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. ANGO: 1.36 )
Ranked among companies with meaningful Quick Ratio only.
ANGO' s Quick Ratio Range Over the Past 10 Years
Min: 1.16  Med: 3.97 Max: 12.12
Current: 1.36
1.16
12.12
Days Inventory 135.65
ANGO's Days Inventory is ranked lower than
57% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.57 vs. ANGO: 135.65 )
Ranked among companies with meaningful Days Inventory only.
ANGO' s Days Inventory Range Over the Past 10 Years
Min: 116.22  Med: 140.45 Max: 174.24
Current: 135.65
116.22
174.24
Days Sales Outstanding 54.53
ANGO's Days Sales Outstanding is ranked higher than
65% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.25 vs. ANGO: 54.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANGO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.92  Med: 59.07 Max: 79.96
Current: 54.53
45.92
79.96
Days Payable 31.74
ANGO's Days Payable is ranked lower than
75% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 48.01 vs. ANGO: 31.74 )
Ranked among companies with meaningful Days Payable only.
ANGO' s Days Payable Range Over the Past 10 Years
Min: 31.74  Med: 55.91 Max: 111.22
Current: 31.74
31.74
111.22

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
ANGO's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. ANGO: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ANGO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29  Med: -12.35 Max: -1
Current: -1.1
-29
-1

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.99
ANGO's Price/Projected FCF is ranked higher than
86% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.95 vs. ANGO: 0.99 )
Ranked among companies with meaningful Price/Projected FCF only.
ANGO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.53  Med: 0.87 Max: 1.11
Current: 0.99
0.53
1.11
Price/Median PS Value 1.05
ANGO's Price/Median PS Value is ranked higher than
61% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. ANGO: 1.05 )
Ranked among companies with meaningful Price/Median PS Value only.
ANGO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.04 Max: 3.13
Current: 1.05
0.67
3.13
Earnings Yield (Greenblatt) (%) 0.41
ANGO's Earnings Yield (Greenblatt) (%) is ranked lower than
58% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. ANGO: 0.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANGO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 4.6 Max: 12.3
Current: 0.41
0.2
12.3
Forward Rate of Return (Yacktman) (%) 5.00
ANGO's Forward Rate of Return (Yacktman) (%) is ranked lower than
63% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.20 vs. ANGO: 5.00 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ANGO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -15.5  Med: 1.2 Max: 7.3
Current: 5
-15.5
7.3

More Statistics

Revenue (TTM) (Mil) $353.9
EPS (TTM) $ -1.21
Beta1.12
Short Percentage of Float2.41%
52-Week Range $9.71 - 17.54
Shares Outstanding (Mil)36.42

Analyst Estimate

May17 May18
Revenue (Mil $) 362 371
EPS ($) 0.63 0.70
EPS w/o NRI ($) 0.63 0.70
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:ANGO

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
Weekly CEO Buys Highlight: JPM, ROG, PBY, ANGO, MCHX Jul 21 2012 
Weekly CEO Buys Highlight: WINA, ANGO, FES, LTS, TBOW Apr 15 2012 
Weekly CEO Buys Highlight: PKY, TWO, UVSP, AGYS, ANGO Feb 19 2012 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 07 2011 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 07 2009 
Weekly CEO Buys Highlight: CoBiz Financial Inc, Winmark Corp, The Greenbrier Companies Inc, AngioDyn Jul 26 2009 
Weekly CEO Buys Highlight: The Greenbrier Companies, AngioDynamics, Hallmark Financial Services, Ves Apr 18 2009 

More From Other Websites
AngioDynamics Hits New 52-Week High on Solid Q4 Results Sep 22 2016
Zacks.com featured highlights: Tenneco, WNS, AngioDynamics, Teleflex and j2 Global Sep 21 2016
AngioDynamics to Report Fiscal 2017 First Quarter Financial Results Sep 21 2016
AngioDynamics to Report Fiscal 2017 First Quarter Financial Results Sep 21 2016
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating AngioDynamics, Inc. for Potential... Sep 19 2016
ETF’s with exposure to AngioDynamics, Inc. : September 15, 2016 Sep 15 2016
ANGIODYNAMICS INC Files SEC form 8-K/A, Change in Directors or Principal Officers Sep 08 2016
AngioDynamics (ANGO) Hits 52-Week High on Positive View Sep 08 2016
AngioDynamics to Present at the 2016 Morgan Stanley Global Healthcare Conference Sep 06 2016
ETF’s with exposure to AngioDynamics, Inc. : August 31, 2016 Aug 31 2016
AngioDynamics on hiring spree at Queensbury plant after competitor's recall Aug 17 2016
AngioDynamics to Present at the 2016 Canaccord Genuity Growth Conference Aug 08 2016
AngioDynamics to Present at the 2016 Canaccord Genuity Growth Conference Aug 08 2016
ANGIODYNAMICS INC Financials Aug 06 2016
ANGIODYNAMICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Aug 05 2016
AngioDynamics Announces Secondary Offering of 2,250,000 Shares of Common Stock by Selling... Aug 01 2016
AngioDynamics Announces Secondary Offering of 2,250,000 Shares of Common Stock by Selling... Aug 01 2016
ANGIODYNAMICS INC Files SEC form 10-K, Annual Report Aug 01 2016
ANGIODYNAMICS INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 28 2016
AngioDynamics Issues Statement Regarding Stryker recall of Angiographic Catheters Jul 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)